Last reviewed · How we verify
NCT03993366
Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement
NA trial testing Fiasp+Pramlintide Closed-Loop System in Type 1 Diabetes Mellitus in 8 participants. Completed in 6 August 2019.
6 August 2019
Quick facts
| Lead sponsor | McGill University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 1 March 2019 |
| Primary completion | 6 August 2019 |
| Estimated completion | 6 August 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Fiasp+Pramlintide Closed-Loop System
- Fiasp Closed-Loop System
Conditions studied
- Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →
Sponsor
McGill University
Who can join
12 and older, any sex, with Type 1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this pilot study is to generate preliminary data of (i) Fiasp-plus-Pramlintide closed-loop system with a simple meal announcement, compared to (ii) Fiasp-alone closed-loop system with full carbohydrate counting, in preparation for an outpatient study over two weeks
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03993366
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 1 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
- NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
- NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
- NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
- NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting
Other McGill University trials
Trials by the same sponsor.
- NCT07178535 — Feasibility of Real-Time Visual Feedback in Augmented Reality to Reduce Gait Asymmetry Post-Stroke · NA · not yet recruiting
- NCT07445841 — Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training · NA · recruiting
- NCT07447830 — The Pain Reduction Using Immersive Virtual Reality During Wound Care Evaluation Study at Maimonides (PRISM) - Pilot Stud · NA · recruiting
- NCT07497425 — Neuroimmune Responses to Exercise in Chronic Back Pain · NA · recruiting
- NCT06994559 — Music as an Adjunct to Ketamine Therapy for Chronic Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03993366 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McGill University
- Last refreshed: 1 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03993366.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing